N&PD Moderators: Skorpio
You should upgrade or use an alternative browser.DXM and Dopamine
themdyaunome
Bluelighter
EDIT: Just had to throw this funny story in here. Many years ago my brother and his friend were taking Coricidin almost daily, and his friend wound up in the hospital two or three times due to the amount of guaifenesin ingested. Anyways, one night I heard something at my bedroom door around 2 or 3 in the morning. I figured it was my cat wanting to come in. I then listened more closely and could hear giggling. I open the door to find my brother and his friend licking my wooden door. They claimed it "felt awesome."MyDoorsAreOpen
Bluelight Crew
... Does your name start with a T???(it's a serious question...)MagickalKat777
Bluelight Crew
... Does your name start with a T???(it's a serious question...)
Low doses of DXM are close to being on par with MDMA for me and a number of people that I know. Dextromethorphan has been found to be active BEFORE it is turned into dextrorphan which implies that it has its own effects (a perfect example is that dextrorphan doesn't release serotonin on its own, at least from my own experiments with DXO and MDMA versus ONE experiment with 150mg of DXM and 100mg of MDMA which I will never repeat - came quite close to full blown serotonin syndrome that time) - also if you read the literature, people that are CYP2D6 deficient have entirely different experiences with DXM (besides the long life of the drug) than those that are not CYP2D6 deficient. I wouldn't be surprised if dopamine was released by DXM before it is converted to DXO. I have also experimented with cimetidine and DXM and found that high dose DXM with cimetidine is also quite euphoric for a number of hours - noting that CYP2D6 is inhibited by cimetidine.
I used to take low dose (200mg approximately) DXM and go dance all night and it was quite similar to a roll but quite a heavy bodyload (tachycardia, much more likely to vomit, higher temperature, etc) - doing the same with higher plateaus of DXM dosing would lead to a full blown psychedelic trip that still retained much milder tachycardia and it felt like a lighter overall bodyload - don't ever ask me to try to dance or talk on 3rd/4th plateau trips though.
... Does your name start with a T???(it's a serious question...)
this is complete utter bullshit. i am on DXM and oxycodone right now. a lower dosage of oxy infact, and it feels 10x times stronger
but no my name starts with an R
source?? in all my studying, i have never found anything about DXM being a dopamine reuptake inhibitorMagickalKat777
Bluelight Crew
lorne667 - yeah I was never dumb enough to try cimetidine and MDMA, just DXM which was dumb enough (albeit much lower dose than I would usually take it was still stupid). It does help to prove my point though. Dextromethorphan is an active drug on its own and it makes sense if you think about the "plateaus" of DXM. Maybe at lower doses, not as much DXM gets nailed by CYP2D6 and converted to DXO - even still, DXO is about 40% more potent by weight in my experiments than DXM. I never tried mixing the two together because I really didn't like the experience of pure DXO that much. Extremely cold. DXM at any level has at least some euphoria for most of its users or it would have died like salvia. Just saying.themdyaunome
Bluelighter
EDIT: thank you for pointing that out laCster. I know I should have taken basic pharmacology english in college. Serotonin, serotonin, serotonin. There we go!sekio
Bluelight Crew
MagickalKat777
Bluelight Crew
EDIT: Does DXM on its own have dopamine activity? I think it does. Nobody has done the proper testing to prove it. There is a reason for this. For one DXM is abused enough but there is its optical? isomer levomethorphan which is a powerful opiate agonist (in the form of levorphanol IIRC) and if someone did the work I'm sure we could turn DXM into LVM. On top of that, its "recommended" use is as an antitussive (even though studies have proven it to be no better than placebo, we still have a drug that was specifically excluded from scheduling for its use in OTCs. Don't fuck it up) prevents research into the DXM -> DXO and beyond science.sekio
Bluelight Crew
Yeah and if someone did the work they could turn my turds into gold ingots too - stereochemistry doesn't work like thatthemdyaunome
Bluelighter
. Maybe at lower doses, not as much DXM gets nailed by CYP2D6 and converted to DXO - even still, DXO is about 40% more potent by weight in my experiments than DXM. I never tried mixing the two together because I really didn't like the experience of pure DXO that much. Extremely cold. DXM at any level has at least some euphoria for most of its users or it would have died like salvia. Just saying.
do you ( or anyone else) know how much DXM is converted into DXO, or the amount converted depends on a person's velocity at which their 2D6 enzymes process?Deleted member 175441
Bluelighter
Dondante
Bluelighter
Interesting, but surprising...check out the study below.
Zawertailo LA, Tyndale RF, Busto U, Sellers EM. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol. 2010 25(1):71-9.
OBJECTIVE:
Variation in the activity of cytochrome P450 2D6 (CYP2D6) affects the pharmacokinetics and effectiveness of dextromethorphan (DM), because it controls the production of dextrorphan, an active metabolite, with higher affinity for the NMDA receptor than the parent compound. This study examined whether pharmacological inhibition of CYP2D6 activity with quinidine would mimic the genetic mutation and thus also alter the psychoactive effects of DM.
METHODS:
In a single-blind, within-subjects study, eight healthy volunteers (all homozygous for the wild type allele for CYP2D6) received placebo and varying doses of DM, both with and without quinidine pre-treatment. Pharmacokinetic and pharmacodynamic measures were assessed at baseline and every hour post-drug for 6 h.
RESULTS:
Compared to the no quinidine condition, quinidine pre-treatment decreased the area under the dose-response curve on subjective measures of positively reinforcing effects (e.g., euphoria, p < 0.04; drug liking, p < 0.05), and was significantly greater for measures of dysphoria (e.g., unpleasantness, p < 0.02). These changes corresponded to increased DM and decreased dextrorphan plasma concentrations.
CONCLUSIONS:
Compared to DM alone, quinidine pre-treatment inhibited DM metabolism and changed its subjective effects, demonstrating that the psychoactive properties of DM are a function of drug metabolism. These results demonstrate the relationship between CYP2D6 activity, plasma drug levels, and psychoactive drug effects, and have implications for both the abuse liability and therapeutic utility of DM.
Here, 2D6 inhibition, which leads to accumumlation of DM (decreased conversion to DXO), was associated with increased measures of dysphoria and decreased measures of drug liking and euphoria. My understanding is that a similar phenomenon occurs in poor metabolizers who experience dysphoric effects from higher doses of DM.
Interestingly, the above combination has recently been put in a pill and marketed (as Nuedexta) for treatment of a type of affect dysregulation called pseudobulbar affect. My sense is that at low doses it essentially functions as an SSRI.